| 6.23 0.22 (3.66%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.75 | 1-year : | 8.24 |
| Resists | First : | 6.64 | Second : | 7.05 |
| Pivot price | 6.36  |
|||
| Supports | First : | 5.96 | Second : | 4.96 |
| MAs | MA(5) : | 6.18 |
MA(20) : | 6.39 |
| MA(100) : | 7.4 |
MA(250) : | 8.36 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 22.5 |
D(3) : | 24.3 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 14.68 | Low : | 5.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NAGE ] has closed above bottom band by 31.8%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.28 - 6.31 | 6.31 - 6.34 |
| Low: | 5.9 - 5.94 | 5.94 - 5.97 |
| Close: | 6.18 - 6.23 | 6.23 - 6.28 |
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Sat, 17 Jan 2026
Can Niagen Bioscience’s (NAGE) HSA Access Shift Redefine Its Direct-to-Consumer Growth Strategy? - Yahoo Finance
Fri, 16 Jan 2026
A Look At Niagen Bioscience (NAGE) Valuation After New HSA And FSA Purchasing Option For Tru Niagen - Sahm
Thu, 15 Jan 2026
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S. - Nasdaq
Thu, 15 Jan 2026
Is Niagen Bioscience (NAGE) Using Investor Summits To Recast Its Healthy Aging Strategy Narrative? - simplywall.st
Mon, 12 Jan 2026
Will Weakness in Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Mon, 05 Jan 2026
Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market (NASDAQ:NAGE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 34 (%) |
| Held by Institutions | 41.2 (%) |
| Shares Short | 5,670 (K) |
| Shares Short P.Month | 5,520 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | 16.3 % |
| Operating Margin | 12.4 % |
| Return on Assets (ttm) | 15.6 % |
| Return on Equity (ttm) | 38.9 % |
| Qtrly Rev. Growth | 32.9 % |
| Gross Profit (p.s.) | 0.99 |
| Sales Per Share | 1.56 |
| EBITDA (p.s.) | 0.25 |
| Qtrly Earnings Growth | 150 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 14 (M) |
| PE Ratio | 25.95 |
| PEG Ratio | 0 |
| Price to Book value | 7.07 |
| Price to Sales | 3.98 |
| Price to Cash Flow | 23.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|